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Abstract
Background: Isoniazide preventive therapy (IPT) is given to individuals with latent infection of tuberculosis (TB) to
prevent the progression to active disease. One of the primary reasons for failure of IPT is poor adherence.
Methods: A cross sectional study was conducted in four hospitals in Addis Ababa. Data were collected using a
pre-tested interviewer-administered structured questionnaire. Bivariate and multivariate analysis was done to
identify predictors of IPT.
Results: A total of 319 (97.5%) individual participated in this study. Within seven days recall period, self-reported
dose adherence rate was 86.5%. Individual who received explanation about IPT from health care providers (OR =
7.74; 95%CI: 3.144, 19.058); who had good feeling/comfortable to take IPT in front of other people [OR = 5.981,
95%CI (2.308, 15.502)] and who attended clinical appointment regularly (OR = 4.0; 95%CI: 1.062, 15.073) were more
likely to adhere to IPT. Participants who developed IPT related adverse effect were 93% less likely to adhere to the
prescribed doses (OR = 0.065; 95%CI: 0.024, 0.179).
Conclusion: The prevalence of self reported dose adherence over the past 7 days was higher. Non-adherence was
observed among respondent who were not provided with sufficient information about IPT. The health care
providers need to strengthen their educational and counseling efforts to convince the patient before putting them
on IPT. To enhance adherence, health education efforts should focus on the importance of IPT, the details of the
regimen and adverse effects.
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Background
Tuberculosis is among the top ten causes of global mor-
tality and morbidity. Recently, 32% of the world’s popu-
lation is infected with TB. Over 95% of new tuberculosis
cases and deaths occur in developing countries where
the highest incidence and number of deaths occur in
Asia and sub-Saharan Africa [1]. HIV/AIDS is the great-
est risk factors for the development of TB. The risk of
reactivation of latent infection of TB is greatly increased
in Africa as a result of the HIV/AIDS epidemic [2-5].
The World Health Organization (WHO) had proposed
a framework of TB/HIV/AIDS collaborative activities to
prevent the occurrence of TB-HIV disease. IPT, intensi-
fied TB case finding, and infection prevention are the
major strategies to control TB in HIV-positive indivi-
duals [6]. Cognizant of this fact, the Ethiopia national
TB/HIV collaboration program adopted these activities
including IPT. The Ethiopian national TB guideline
recommends that Isoniazide (INH) should be given to
patients daily at a dose of 5 mg/kg, a maximum dose of
300 mg/day for a period of 6 months. Pyridoxine at a
fixed daily dose of 25 mg is indicated in order to reduce
the risk of developing INH-induced peripheral neuropa-
thy [7]. Tuberculosis preventive therapy should only be
considered in areas that have a good functioning of
tuberculosis program [8]. There is now strong evidence
from several randomized controlled trials about the effi-
cacy of preventive therapy in the prevention of
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nodeficiency virus. However, one of the primary reasons
for failure of IPT is poor adherence. Accurate assess-
ment of adherence and its associated factor is a neces-
sary first step towards improving adherence to IPT [9].
There is limited knowledge in Ethiopia about the rate of
adherence to IPT and its determinants. The aim of this
study was to address this knowledge gap using a multi-
center study in Addis Ababa, Ethiopia.
Methods
Study setting and participants
A cross sectional study was conducted in Yekatit 12,
Zewditu, Gandi and Minilik hospitals in Addis Ababa
from February 1 to March 30, 2010. The study hospitals
are among the biggest in Ethiopia and serving the
majority of the HIV/AIDS clients in the country. The
hospital records showed that from the total of 1808
adults taking IPT in the whole Ethiopia, 1303 of them
were attending in these hospitals.
The source populations were People Living with HIV/
AIDS (PLHA) without active TB attending the ART
clinics of the study hospitals and, who were on IPT and
on follow up during the study period. The study popula-
tion was sampled adults who were receiving IPT and
fulfilling the inclusion criteria in the study hospitals.
Adult (> = 18 years) HIV positive individuals who were
taking IPT for at least one month before the initiation
of the study were included in the study. Individuals who
had been taking IPT for less than a month and/or were
seriously sick were excluded from the study.
Sample size and sampling technique
The sample size was calculated using Epi-Info 6.04 sta-
tistical software with the assumptions of adherence rate
of 50%, 5% margin of error and 95% confidence interval
and 10% for non-response rate. This gave us a total
sample size of 327. This sample size was distributed to
the selected hospitals according to the number of
patients proportionally. All HIV positive individuals
attending the TB/HIV clinics of the selected hospitals
and who fulfilled the entry criteria were identified from
clinics using their identification number as a sampling
frame. From the sampling frame, participants were
selected using simple random sampling technique.
Data collection process
Data were collected by trained public health officers
using a structured and pre-tested questionnaire. The
questionnaire contained dependent and independent
variables and was originally developed in English; and
then translated into Amharic and back translated to
English by other person who was blind to the original
questionnaire to check for its consistency. The
dependent variable was self-reported adherence to IPT
in the last 3, 7 and 30 days. The independent variables
included: socio-demographic variables, medication
adverse effect, emotional and social support, conveni-
ence of regimen (the duration, dose, and frequency),
knowledge about IPT and understanding the important
of adherence; belief on the efficacy of medication; sub-
stance use such as Khat(Catha Edulis), alcohol, and
cigarette; patient and physician relationship.
The percent of adherence was calculated for each drug
by dividing the number of pills taken by the number of
pills prescribed. Then, the percent of adherence to the
IPT was estimated by the average adherence rate to the
drugs.
Data analysis
The data were entered into SPSS 16.0, edited, and
cleaned thoroughly and analyzed. The analysis consisted
of basic summaries of patient characteristics, bivariate
and multivariate analysis of the relation between adher-
ence and various factors. All explanatory variables that
were significantly associated with the outcome variable in
the bivariate analyses (P < 0.05) were entered in stepwise
logistic regression model to identify independent predic-
tor of adherence. In this study, patients who report an
intake of 80% or more of the prescribed medication over
past 3 and 7 days were considered to be adherent, while a
patient who reported an intake of less than 80% of the
prescribed doses over the past 3 and 7 days were consid-
ered to be non adherent [10]. Adverse effect was also
defined as an unwanted effect caused by the administra-
tion of INH such as numbness as a result of neuropathy,
sign of liver toxicity, rash, nausea, and seizure. Ethical
Clearance was obtained from Institutional Ethical Review
Committee of Jimma University and ethical review com-
mittee of Addis Ababa Health Bureau.
Results
Characteristics of the study subjects
Of the proposed study participants, 319 (97.5%) were
included in this study. One hundred and twenty-four
(38.9%) were males and their age ranged from 22 to 71
years with the mean (SD) age of 38(± 10.6). Orthodox
was the dominant religion (84.3%) and 125 (39.2%) were
married. Almost half 172(53.9%) of the respondents
were Amhara, and more than half of the respondent 203
(63%) had average monthly income of less than 35.5
USD (1US $ = 17Birr), 94(29.5%) were grade 1-8 educa-
tional level, and 114(35.7%) were private institution
employee (Table 1).
Patient report on adherence to IPT
As shown in Table 2, the 3 days, 7 days, and the past 1
month self-reported adherence rate was 281(88.1%), 276
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number of doses missed in the past 3 days, 7 days and 1
month prior to the study was 1.84[SD ± 0.75], 2.64[SD
± 0.1.71] and 6.3[SD ± 7.31] respectively. Of the total
participants, 66 (20.7%) had history of missed days
(missed one or more doses of isoniazide in the past 3
days, 7 days, in the last 1 month prior to enrolment in
study)(Table 3). The most frequently mentioned reasons
for missing pills were side effect (18.19%, N = 12), being
too busy to take the drug (22.72%, N = 16), forgetfulness
(24.24%, N = 15), perceived long duration of treatment
(13.63%, N = 9), being away from residential area
(15.16%, N = 10) and lack of advice by doctors (6.06%,
N = 4) (Figure 1).
Factors independently associated with adherence to IPT
Individual who had receive explanation about IPT were
8 times more likely to be adherent as compared to those
who did not receive (OR = 7.740; 95%) CI: (3.144,
19.058). Patients who developed IPT related adverse
effects were 93% less likely to adhere to the prescribed
doses (OR = 0.065; 95%CI: 0.024, 0.179). Study partici-
pants who had good feeling/comfortable to take IPT
drug in front of others people were 6 times more likely
Table 1 Basic socio-demographic attributes of the cross-
sectional survey at Addis Ababa governmental hospitals,
Addis Ababa, May 2010
Socio-demographic Variables Frequency (%)
Sex (n = 319)
Male 124(38.9%)
Female 195 (61.1%)
Age 38.7 (+ 10.6) yrs (n = 319)
<2 5 16(5)
25-34 110 (34.5)
35-44 85 (26.6)
≥45 108 (33.9)
Ethnicity (n = 319)
Oromo 71 (22.3)
Ahmara 172 (53.9)
Tigre 48(15)
Others
# 28 (8.8)
Religion (n = 319)
Orthodox 269 (84.3)
Protestant 33 (10.3)
Muslim 15(4.7)
Catholic 2(0.6)
Marital status (n = 319)
Single 66(20.7)
Married 125 (39.2)
Divorced 39 (12.2)
Widowed 89 (27.9)
Educational status(n = 319)
Illiterate 40 (12.5)
Grade 1-8 94 (29.5)
Grade 9-10 39 (12.2)
Grade +10 and certificate 93 (29)
Diploma and above 52 (16.3)
Occupational status(n = 319)
House wife 60 (18.8)
Student 3 (0.9)
Government employment 44 (13.8)
Private employee 114 (35.7)
Merchant 14(4.4)
Driver 5 (1, 6)
No jobs 71(22.3)
Others* 8(2.3)
Monthly income(n = 319) in USD
$
> = 35.5 203(63.6)
< 35.5 116(36.4)
#Affar, Guragie, Somali, Welaita
*Clerical, Sales and services, Manual labor, Agriculture
$Exchange rate 1 USD = 17 Ethiopian Birr (ETB)
Table 2 IPT adherence status by self-reports of the cross-
sectional survey at Addis Ababa governmental hospitals,
Addis Ababa, May 2010
Duration Adherent
Frequency
(%)
Non-adherent
Frequency (%)
Total
Frequency
(%)
Past three
days
281(88.1) 38(11.9) 319(100)
Past 7 days 276(86.5) 43(13.5) 319(100)
Past one
month
255(79.9) 64(20.1) 319(100)
Table 3 Frequency table that shows patient’s adherence
practice of the cross-sectional survey at Addis Ababa
governmental hospitals, Addis Ababa, May 2010
Variables Frequency (%)
History of missed days
Yes 66(20.7)
No 253(79.3)
Time of missing prior to interview to interview
Within the first week 29(51.8)
Between 1-2 month 17(30.4)
Between 3-5 months 4(7.1)
Above 5 months 2(3.6)
I don’t know 4(7.1)
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95%CI: 2.308, 15.502) and those who attend clinical
appointment regularly were 4 times more likely to
adhere to IPT compared to those who did not attend
regularly (OR = 4.001; 95%CI: 1.062, 15.073) (Table 1).
Discussion
We tried to assess the rate of adherence to IPT and its
determinants among HIV positive adults in the capital
city of Ethiopia. We use self-reported dose adherence
due to its ease of practicality, low cost, readiness to
obtain the desired information, and to identify patients’
at risk for non-adherence [11]. This study revealed an
overall prevalence rate of IPT adherence rate of 276
[86.5%] over the past 7 days prior to the interview. In
the operational assessment of adherence among HIV
infected individual in Uganda, adherence rate of 38%
was reported [11]. A facility based cross-sectional study
in rural South Africa also found that only 47.1% were
adherent to isoniazid preventive therapy [12]. In a pro-
spective cohort study in Thailand using daily isoniazid
for 6 months, 31% failed to complete the 9-month regi-
men [13]. In contrast to these, a cross-sectional study in
South Africa revealed relatively similar finding with the
present study with overall rate of self reported adher-
ence rate of 72%[14] and a randomized control trail of
adherence to IPT among HIV patient in Uganda also
showed similar finding with adherence rate of 88% [15].
This may be due to the fact that majority of the respon-
dent had receive the information about isoniazide pre-
ventive therapy and perceived benefit of the medication.
In addition, it might be also due to the great emphasis
given to the TB-HIV collaborative activity by the
government and implementing partners. In the current
study, different reasons for missing pills such as forget-
fulness, being buss, and away from home were reported
which is consistent with the findings of other studies
[16,17]. In our study, patients’ who didn’t miss clinic
appointment were more likely to complete their regimen
which is similar to a study elsewhere [18].
According to a study conducted in Kenya and Zambia,
the poor quality of physicians’ interpersonal skills has
been shown to negatively affect adherence [19,20]. Four
cross-sectional studies showed the impact of poor
patient-physician relation on adherence in different set-
ting [21-24]. Randomized trial also showed that an
increase in non-adherence in situations where doctors
appear insensitive, use medical jargon, view patients as
complainers, or do not provide clear messages about the
cause of the illness or reasons for treatment [25,26].
Stigma or uncomfortable to take drug in front of others
was one of the factors for adherence to IPT. A stigma
attached to TB in China leads to imposition of socio-
physical distance and participatory restrictions on those
suffering from the disease [27] and social and family
support positively influenced adherence [12] and reasons
for low adherence to preventive INH treatment, other
than side effects, include fear of stigma [18,28]. Patients’
who developed side effect were less likely to complete
the prescribed regimen. A systematic review of rando-
mized trial showed that adherence has been shown to
decrease with increased concerns about the toxicity of
anti-TB medications and fear of side effects [15]. It is
possible that minor adverse effects, which did not pose
a danger in the clinician’s view, nevertheless resulted in
discomfort and contributed to a patients’ decision not to
Figure 1 Reasons given for missing to take IPT among people living with HIV in Addis Ababa government hospitals, Addis Ababa,
May 2010.
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worse among those with side effects [30,31]. Patient
reports of minor treatment side effects should alert clin-
icians to reassess and discuss the benefits and the risks
of therapy as patient beliefs about the necessity of ther-
apy and concerns about potential adverse effects is a
stronger predictor of medication adherence than clinical
or socioeconomic factors [32]. Knowledge about the
regimen and the disease has significant association with
adherence which was inconsistent with the study con-
ducted in Uganda [15]. A cross-sectional study in South
Africa also showed no significant association between
patients’ knowledge about the treatment and the disease
with adherence [14]. Knowledge and attitudes towards
tuberculosis were not significant predictors in United
States [33]. A study conducted to assess factors contri-
buting for poor compliance also showed that knowledge
and attitude towards tuberculosis were not significant
predictors of adherence [34]. However, other studies
reported that beliefs and attitudes may be more impor-
tant than side effects in predicting adherence and influ-
encing health behavior [18,35,36]. Studies reported that
patient’s compliance with therapy is affected by issues of
belief, health motivation, perceived susceptibility to dis-
ease and its severity, views in the benefit of professional
intervention and knowledge of the condition [37,38]. It
has been documented that when patients’ know about
the importance of complying with drug therapy and
their adherence to the prescribed regimen is improved
[39]. In similar study in India, it was found that there
was an association between the compliance behavior of
the patients’ and their knowledge of specific aspects of
the disease [40]. patients’ who perceive their illness to
be more serious and who believe that treatment will
alleviate the condition are more likely to be compliant
[41]. These discrepancies/inconsistencies among differ-
ent studies may be due to difference on educational sta-
tus, health service coverage, and access to health related
information and level of economic growth across coun-
tries. Poor knowledge about treatment regimens and
patient perception of benefits obtained from therapy
was significantly associated with non adherence
[12,40,42-45]. This might be due to differences in the
study design. Knowledge of factors associated with poor
compliance can help to identify groups at risk of
defaulting and lead to improved patients’ education.
Belief in isoniazide (INH) safety was associated with a
positive test and patients who believed INH is important
for prevention of TB disease were more likely to be
negative urine results [14]. Completers were motivated
by understanding the importance of IPT and counseling
[28].
This study had some limitations. First, since there is
no a “gold standard” for assessment of adherence, we
used self-reported adherence which might introduce
recall bias. Second, the cross sectional nature of our
study may not establish cause effect relationship.
D e s p i t et h ea b o v el i m i t a t i o n s ,t h es t u d yh a ds e v e r a l
strengths, including using a relatively large sample size,
inclusion of several sites, inclusion of several variables
and review of available medical charts.
Conclusion
Adherence rate in Addis Ababa is higher than most stu-
dies in Africa. However, stigma, lack of provider-client
communication, irregular clinic attendance and fear of
side effects of the medication were the best predictor’s
of non-adherence. Health workers and the ministry of
Table 4 Independent predictors of adherence to IPT among people living with HIV in Addis Ababa government
hospitals, Addis Ababa, May 2010
Variable Adherent
Frequency
(%)
Non-
adherent
Frequency
(%)
Crude/unadjusted OR
(95%CI)
p-value Adjusted OR
(95%CI)
p-value
Did the regimen explained to you
Yes 227(93) 17(7) 7.085(3.57, 14.05) < 0.001 7.74(3.14, 19.06) < 0.001
No 54(72) 21(28) 11
Adverse effect
Yes 19(55.9) 15(44.1) 0.07(0.03, 0.16) < 0.001 0.06(0.02, 0.18) < 0.001
No 262(91.9) 23(8.1) 11
Feel comfortable to take drug in front of
others
Yes 169(98.8) 28(1.2) 7.53(3.24, 17.52) < 0.001 5.98(2.31, 15.50) < 0.001
No 112(75.7) 10(24.3) 11
Attend clinical appointment regularly
Yes 265(90.1) 29(9.9) 4.30(1.76, 10.49) < 0.001 4.00(1.06, 15.07) 0.04
No 15(62.5) 9(37.5) 11
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tion messages on the aforementioned risk factors for cli-
ents to promote better adherence.
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